BioCryst Pharmaceuticals announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. This multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the urate-lowering activity and safety of BCX4208 20mg, 40mg, and 80mg doses alone and in combination with allopurinol 100mg, 200mg, and 300mg doses administered once-daily in patients with gout for 21 days.
BCX4208 is a next generation purine nucleoside phosphorylase (PNP) inhibitor with the potential for once-a-day dosing suitable for chronic administration. Previous studies have shown that BCX4208 may have utility in diseases dependent on T-cells, B-cells, or uric acid.
For more information call (205) 444-4600 or visit www.biocryst.com.